Benzinga | Apr 29, 2021 09:01AM EDT

Truist Securities Downgrades Adverum Biotechnologies to Hold, Lowers Price Target to $9

Truist Securities analyst Joon Lee downgrades Adverum Biotechnologies (NASDAQ:ADVM) from Buy to Hold and lowers the price target from $30 to $9.